Increased expression of peroxiredoxin 6 and cyclophilin A in squamous cell carcinoma of the tongue

Oral Diseases

Volumn 17, Issue 3, 2011, Pages 328-334

  Huang, C F ^a   Sun, Z J ^a   Zhao, Y F ^a   Chen, X M ^a   Jia, J ^a   Zhang, W F ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

CypA; PRDX 6; Prognosis; Tongue cancer

Indexed keywords

CYCLOPHILIN A; PEROXIREDOXIN 6;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CERVICAL LYMPH NODE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; CELL NUCLEUS; CYCLOPHILIN A; CYTOPLASM; CYTOSOL; DILATATION, PATHOLOGIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PEROXIREDOXIN VI; PROGNOSIS; SURVIVAL RATE; TONGUE; TONGUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79952595142     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2010.01730.x     Document Type: Article

References (33)

1. Barnes L, Eveson JW, Reichart P, Sidransky D (2005). World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. IARC Press: Lyon, pp.168-175.
2. Campa MJ, Wang MZ, Howard B, Fitzgerald MC, Patz EF (2003). Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin A as potential molecular targets in non-small cell lung cancer. Cancer Res 63: 1652-1656.
3. Chang XZ, Li DQ, Hou YF et al (2007). Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res 9: R76.
4. Chen J, He QY, Yuen AP, Chiu JF (2004). Proteomics of buccal squamous cell carcinoma: the involvement of multiple pathways in tumorigenesis. Proteomics 4: 2465-2475.
5. Choi KJ, Piao YJ, Lim MJ et al (2007). Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia- and cisplatin-induced cell death. Cancer Res 67: 3654-3662.
6. Evans MD, Dizdaroglu M, Cooke MS (2004). Oxidative DNA damage and disease: induction, repair and significance. Mutation Research-Reviews in Mutation Research 567: 1-61.
7. Fujita Y, Nakanishi T, Hiramatsu M et al (2006). Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res 12: 6415-6420.
8. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW (1984). Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 226: 544-547.
9. Hoogsteen IJ, Marres HAM, Bussink J, van der Kogel AJ, Kaanders JHAM (2007). Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review. Head and Neck-Journal for the Sciences and Specialties of the Head and Neck 29: 591-604.
10. Kim SJ, Shin HJ, Jung KY et al (2007). Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue. Jpn J Clin Oncol 37: 812-819.
11. Kinnula VL, Lehtonen S, Sormunen R et al (2002). Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol 196: 316-323.
12. Klaunig JE, Xu Y, Isenberg JS et al (1998). The role of oxidative stress in chemical carcinogenesis. Environ Health Perspect 106 (Suppl 1): 289-295.
13. Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI (2004). Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 172: 989-999.
14. Lee SP, Hwang YS, Kim YJ et al (2001). Cyclophilin a binds to peroxiredoxins and activates its peroxidase activity. J Biol Chem 276: 29826-29832.
15. Lehtonen ST, Svensk AM, Soini Y et al (2004). Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer 111: 514-521.
16. Li DQ, Wang L, Fei F et al (2006a). Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatographyion trap-mass spectrometry. Proteomics 6: 3352-3368.
17. Li M, Zhai QH, Bharadwaj U et al (2006b). Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD 147. Cancer 106: 2284-2294.
18. Li Z, Zhao X, Bai S et al (2008). Proteomics identification of cyclophilin a as a potential prognostic factor and therapeutic target in endometrial carcinoma. Mol Cell Proteomics 7: 1810-1823.
19. Lim SC, Choi JE, Kang HS, Si H (2010). Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma. Int J Cancer 126: 1582-1595.
20. Manevich Y, Feinstein SI, Fisher AB (2004). Activation of the antioxidant enzyme 1-CYS peroxiredoxin requires glutathionylation mediated by heterodimerization with pi GST. Proc Natl Acad Sci USA 101: 3780-3785.
21. Nesterova M, Johnson N, Cheadle C, Cho-Chung YS (2006). Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim Biophys Acta 1762: 398-403.
22. Neumann CA, Fang Q (2007). Are peroxiredoxins tumor suppressors?. Curr Opin Pharmacol 7: 375-380.
23. Nordfors K, Haapasalo J, Helen P et al (2007). Peroxiredoxins and antioxidant enzymes in pilocytic astrocytomas. Clin Neuropathol 26: 210-218.
24. Quan C, Cha EJ, Lee HL, Han KH, Lee KM, Kim WJ (2006). Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol 175: 1512-1516.
25. Ralat LA, Manevich Y, Fisher AB, Colman RF (2006). Direct evidence for the formation of a complex between 1-cysteine peroxiredoxin and glutathione S-transferase pi with activity changes in both enzymes. Biochemistry 45: 360-372.
26. Roh JL, Cho KJ, Kwon GY et al (2009). The prognostic value of hypoxia markers in T2-staged oral tongue cancer. Oral Oncol 45: 63-68.
27. Shoshan SH, Admon A (2007). Novel technologies for cancer biomarker discovery: humoral proteomics. Cancer Biomark 3: 141-152.
28. Shukla S, Govekar RB, Sirdeshmukh R et al (2007). Tumor antigens eliciting autoantibody response in cancer of gingivo-buccal complex. Proteomics Clin 1: 1592-1604.
29. Shukla S, Pranay A, D'Cruz AK, Chaturvedi P, Kane SV, Zingde SM (2009). Immunoproteomics reveals that cancer of the tongue and the gingivobuccal complex exhibit differential autoantibody response. Cancer Biomark 5: 127-135.
30. Wei KJ, Zhang L, Yang X et al (2009). Overexpression of cytokeratin 17 protein in oral squamous cell carcinoma in vitro and in vivo. Oral Dis 15: 111-117.
31. Wood ZA, Schroder E, Robin Harris J, Poole LB (2003). Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci 28: 32-40.
32. Yang HR, Cben H, Yang JC, Qiao SY, Zhao SY, Yu L (2007). Cyclophilin A is upregulated in small cell lung cancer and activates ERK1/2 signal. Biochem Biophys Res Commun 361: 763-767.
33. Zhang QZ, Zhang ZF, Rao JY et al (2004). Treatment with siRNA and antisense oligonucleotides targeted to Hif-1 alpha induced apoptosis in human tongue squamous cell carcinomas. Int J Cancer 111: 849-857.